Amendia announces completion of SpineSelect acquisition (Healio)
Amendia announced recently it has finalized the acquisition of certain assets of SpineSelect LLC.
SpineSelect focuses on providing minimally-invasive systems, implants and instruments, and the acquisition allows Amendia to broaden its product portfolio to include a minimally-invasive transforaminal lumbar interbody fusion system, according to a press release.
Through the acquisition, Amendia will gain 20 patents covering SpineSelect’s core group of products, along with other spinal technologies.
SpineSelect’s minimally-invasive transforaminal lumbar interbody fusion (MITLIF) system comprises two product families: the Marquise MIS Channel System and the Turbo MIS TLIF System. The Marquise MIS Channel System is designed to satisfy the conflicting goal of limiting muscle damage while providing a surgeon adequate access to complete a surgery. The Turbo system has standalone FDA clearance and is designed to overcome deficiencies of stability and rollover, insertion safety, poor visualization, kyphosis and subsidence, according to the release.
Reference: www.amendia.com.